"ctDNA is a risk signal, not yet a treatment compass?" @DrYukselUrun
KEYNOTE-B15 #ESMO26 ctDNA: clearance 82.1% vs 66.7%, EV+pembro vs gem-cis; pCR if ctDNA-neg presurgery 72.4% vs 43.7%. Exploratory.
Reactions + slides: https://hubs.ly/Q04Ccl_50
@Merck @AstellasUS @tompowles1
173 浏览 · 2 赞 · 1 转发 · 0 回复
ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin
https://esmocongress.esmo.org- **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
https://esmocongress.esmo.org来源：KOL Pulse AI · x.com